Industrials / Specialty Industrial Machinery

Xylem Inc. (XYL)

$110.29
+1.81%
$26.0B
Market Cap
27.2
P/E Ratio
1.08
Beta
1.57%
Dividend Yield
Piotroski 6/9Altman Z 4.3 SafeBeneish M -2.51 CleanROIC−WACC -5.2%

Quantitative Summary

Deterministic

At 27.2x earnings — a 39% discount to the sector average of 44.7x — XYL is in the lower valuation range. Financial health is average: Piotroski 6/9, Altman Z 4.3. DCF fair value of $98 implies 24% downside based on model assumptions.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of Xylem Inc. reveal a capital allocation challenge where the return on invested capital at 6.5% falls significantly short of the cost of equity, creating a negative spread that erodes long-term shareholder value despite an ROE of 8.2%. This profitability is primarily driven by robust net margins of 10.6% and strong gross margins near 39%, rather than asset efficiency or financial leverage, as indicated by the DuPont decomposition showing low turnover at 0.51x and moderate equity multipliers around 1.5x. While qualitative risk metrics remain stable with a solid Piotroski F-Score of 6/9, an Altman Z-Score of 4.2 suggesting reasonable solvency, and a negative Beneish M-Score pointing to low earnings manipulation risk, the underlying capital destruction persists.

Valuation multiples reflect this operational disconnect; trading at roughly 31 times forward earnings, the stock commands a substantial premium relative to its Industrials sector average of 44.2x, yet remains below historical norms if implied growth rates are not met. The market appears to price in aggressive future performance, assuming a ten-year free cash flow compound annual growth rate of nearly 18%, which starkly contrasts with the current DCF fair value implying downside risk rather than upside potential. This divergence suggests that current pricing relies heavily on optimistic long-term trajectory assumptions that may not align with the company's present capital efficiency profile.

Risk-adjusted performance metrics further complicate the investment thesis, as the stock exhibits a negative Fama-French Alpha of -13.83% annually and underperforms on momentum factors despite holding value characteristics indicated by its HML tilt. Although insider activity has been neutral over the last ninety days with no significant net flow, the combination of capital destruction relative to WACC and below-average risk-adjusted returns presents a challenging setup for investors seeking efficient growth within the industrial space.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive
Market Price
$110.29
Fair Value
$97
Implied Upside
-12.5%
$97IMPLIED FAIR VALUEFAIRLY VALUEDOVERUNDER
Growth Rate (Y1–5)22%
-10%20%50%
Discount Rate (WACC)11.7%
5%12.5%20%

5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.

Reverse DCFMarket-Implied
19.0%annual FCF growth priced in at $110.29

The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 6% YoY revenue.

Sensitivity Matrix

TG ↓ / WACC →9.7%11.7%13.7%
2%$116$90$73
3%$130$98$78
4%$149$108$84

Center = base case. Green = >10% upside, Red = >10% downside vs $110.29.

Pre-computed DCF: WACC=11.7%, terminal growth 3%. Fair value $98 (-24.0%). Not investment advice.

Valuation Context

27.2x
XYL P/E
44.7x
Sector Avg
32.3x
5Y Avg P/E
-39%
vs Sector

Currently trading 1% above its 5-year average P/E of 32.3x.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Technical Setup

AI Generated

XYL is currently trading below both its 50-day and 200-day simple moving averages, indicating a downtrend in the short to medium term, while the Relative Strength Index (RSI) at 33.7 suggests that the stock might be oversold on a near-term basis.

RSI (14)
SMA 50
SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals
4.3
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.51
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

38.5%
Gross Margin
10.6%
Net Margin
6.5%
ROIC
11.7%
WACC
ROIC − WACC Spread: -5.2%— Negative spread.
+5.5%
Revenue Growth (YoY)
+7.5%
Earnings Growth (YoY)
910.0M
Free Cash Flow
43%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

10.6%
Net Profit Margin
NI ÷ Revenue
×
0.51x
Asset Turnover
Revenue ÷ Assets
×
1.50x
Equity Multiplier
Assets ÷ Equity
=
8.2%
Return on Equity
Balanced ROE composition across margins, turnover, and leverage.

Balance Sheet Health

0.50x
Debt / Equity
1.63x
Current Ratio
41.7x
Interest Coverage
-0.0x
Net Debt / EBITDA
2.91%
FCF Yield
1.8B
EBITDA

Earnings Surprise History

Q4
✓ Beat
Est: $0.95
Act: $1.03
+8.0%
Q3
✓ Beat
Est: $1.15
Act: $1.26
+9.9%
Q2
✓ Beat
Est: $1.23
Act: $1.37
+11.1%
Q1
✓ Beat
Est: $1.41
Act: $1.42
+0.8%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Dividend History

$0.4300
Latest Dividend
$1.60
2025 Total
+11.1%
YoY Growth
9 yrs
Consecutive Increases
Annual Dividends per Share
$0.31
2016
$0.72
2017
$0.84
2018
$0.96
2019
$1.04
2020
$1.12
2021
$1.20
2022
$1.32
2023
$1.44
2024
$1.60
2025
$0.86
2026
DateAmountChange
2026-05-28$0.43000.0%
2026-02-24$0.4300+7.5%
2025-11-25$0.40000.0%
2025-08-28$0.40000.0%
2025-05-29$0.40000.0%
2025-02-18$0.4000+11.1%
2024-11-26$0.36000.0%
2024-08-29$0.36000.0%
2024-05-30$0.36000.0%
2024-02-20$0.3600+9.1%
2023-11-20$0.33000.0%
2023-08-30$0.33000.0%

Dividend and split data from SEC filings and market data. Amounts are per share, not adjusted for splits. Source: yfinance.

Risk Profile

25.6%
Annual Volatility
0.62
Sharpe (1Y)
-22.7%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

0.96
Market β
Mkt-RF
+0.303
Size (SMB)
Small-cap tilt
+0.136
Value (HML)
Value tilt
+0.372
Profit (RMW)
Robust
+0.023
Invest (CMA)
Neutral
Alpha (annual): -13.83%
R²: 44.6%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

18.0
Forward P/E
1.55
PEG Ratio
2.32
Price/Book
2M
Avg Volume
$154.27
52W High
$105.29
52W Low
10%
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$4.2B
Tracked Passive Exposure
8
ETFs Holding XYL
0.07%
Avg Weight in ETFs
$6.3T
Total ETF AUM

When investors buy or sell ETFs like VOT or XLI, the fund manager is mechanically forced to buy or sell XYL shares regardless of Xylem Inc.'s individual fundamentals. We estimate $4.2B of passive capital is structurally linked to XYL through 8 tracked ETFs. Index rebalances and ETF creation/redemption cycles can create noticeable volume spikes unrelated to company news.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in Xylem Inc. to visualize passive redemption contagion across ETFs and collateral stocks.

XYL Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
XYLEpicenterVTIETFVOOETFIVVETFCATLow RiskCATLow RiskGELow RiskVRTLow RiskGEVLow Risk
XYL Price Drop (%)0

If Xylem Inc. (XYL) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies CATERPILLAR INC (CAT) as the most exposed collateral stock, sharing 1 ETFs with XYL. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 28 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

XYL Ownership Dynamics

Passive funds hold 1 in every 6 XYL shares, reducing daily market volatility.

Ticker
XYL
Total Shares
238M
ETF Lock-Up
15.6%
Display Mode
Total Float Impact
15.6%Locked Float

Xylem Inc. (XYL) exerts notable gravity on the passive index market, currently representing 0.7% of the VOT (VOT) and 0.5% of the State Street Industrial Select Sector SPDR ETF (XLI). Across 28 tracked ETFs, approximately 37M shares (15.6% of float) are held by passive funds and rarely trade on the open market. This level of passive ownership means index rebalances can create outsized volume events.

Float lock-up computed from 28 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

XYL Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
XYL
PRICE
$110.29
FLOOR (POC)
$140.13
STRENGTH
High
$107$109$111$110.29$114$116$119$1219%$1236%$1267%$12810%$1317%$133$135$1389%$140POC 15%$1439%$145$147$150$152
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for Xylem Inc. over the past year sits near $140.13 (15% of 252-day volume). The current price of $110.29 sits 21.3% below the POC — suggesting potential mean-reversion upside if institutional demand reasserts at this level. The highly concentrated volume profile (15% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

XYL Capital Efficiency

How efficiently does Xylem Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$910M
EBITDA
$1.8B
FCF Conversion
51%
Reinvestment Rate
49%
51% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
6.5%
ROIC − WACC Spread
-5.2%

Xylem Inc. converts 51% of its EBITDA into free cash flow, a healthy conversion rate indicating efficient capital management — the business generates substantial cash after reinvestment. However, the ROIC-WACC spread is negative (-5.2%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-111,647$113.73$187,313.31
2026-05-041$115.37$115.37
2026-04-30293$115.40$33,812.2
2026-04-281,315$123.51$162,415.65
2026-04-2718,535$121.46$2.3M
2026-04-2473$121.69$8,883.37
2026-04-23690$121.46$83,807.4
2026-04-21593$120.46$71,432.78
2026-04-15165$129.66$21,393.9
2026-04-108,416$129.40$1.1M
2026-04-081,790$124.27$222,443.3
2026-04-0629,799$121.26$3.6M
2026-03-2761$119.49$7,288.89
2026-03-2525$120.45$3,011.25
2026-03-1346,238$120.02$5.5M
2026-03-092,403$123.15$295,929.45
2026-03-04207$127.18$26,326.26
2026-02-1820,544$128.18$2.6M
2026-02-1135,828$128.92$4.6M
2026-02-039,741$139.88$1.4M
2026-01-20280$146.13$40,916.4
2025-11-26818$141.51$115,755.18
2025-11-2593,222$141.83$13.2M
2025-11-249$140.39$1,263.51
2025-11-1710,304$142.73$1.5M
2025-11-138,531$149.87$1.3M
2025-11-122,704$149.78$405,005.12
2025-10-30493$152.95$75,404.35
2025-10-291,305$150.50$196,402.5
2025-10-288,574$149.40$1.3M

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
AME0.5630.433Moderate
AMP0.5290.583Moderate
IR0.5190.575Moderate
EMR0.5100.503Moderate
WAB0.5010.516Moderate
RJF0.4850.575Moderate
CMI0.4800.474Moderate
PH0.4780.454Moderate
EWBC0.4770.500Moderate

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare XYL to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.